Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase 1, Open Label, Dose Escalation and Cohort Expansion First in Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti LAG 3 mAb) Administered Alone or in Combination with REGN2810 (anti PD 1 mAb) in Patients with Advanced Malignancies
NCT Number:
NCT03005782
Phase:
I
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Anus, Bladder, Bones and Joints, Brain and Nervous System, Breast, Cervix Uteri, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Hodgkin's Lymphoma, Ill-Defined Sites, Kaposi's Sarcoma, Kidney, Larynx, Leukemia, other, Lip, Oral Cavity and Pharynx, Liver, Lung, Lymphoid Leukemia, Melanoma, Skin, Multiple Myeloma, Mycosis Fungoides, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Hematopoietic, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Unknown Sites
Study Objectives:
To evaluate safety and PK in order to determine an RP2D of REGN3767 as monotherapy and in combination with REGN2810 in patients with advanced malignancies, including lymphoma.
To assess preliminary anti-tumor activity of REGN3767 alone and in combination with REGN2810 (separately by cohort) as measured by ORR.
Study Documents
(MUSC NetID required for document access)